1.09
+3.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Talphera
From its filings with the US Securities and Exchange Commission
Talphera is based in San Mateo, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TLPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $28,000 and a net loss of $14.3m. At that date it held total assets of $29.7m and shareholders' equity of $17.0m.
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.
Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We have two pre-filled syringe product candidates that have been explored but are being evaluated for discontinuation.
Received an investigational device exemption, or IDE, and Breakthrough Device Designation from the United States Food and Drug Administration, or FDA, and registrational trial is ongoing with completion expected in 2026.
IND will be evaluated for submission following toxicology evaluation to enable Phase 2 study.
We are developing Niyad to become the first and only FDA-approved regional anticoagulant for use in adult patients undergoing CRRT. Niyad is infused into the extracorporeal circuit, such as the dialysis circuit during CRRT for acute kidney injury, or AKI, patients in the hospital. In the future, Niyad may have benefit for use in chronic kidney disease patients undergoing intermittent hemodialysis, or IHD, in dialysis centers. Our initial priority is for use during CRRT, which is the focus of the current registrational study.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Feb 2011
- Employees
- 19
- Website
- acelrx.com ↗
- Head office
- 1850 GATEWAY DRIVE, SAN MATEO, CA, 94404
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Adrian AdamsIndependent Chairman of the Board$80,806
- Mr. Vincent AngottiChief Executive Officer, Director, since 2017$1.0m
- Mr. Raffi AsadorianChief Financial Officer$709,857
- Dr. Shakil AslamChief Development Officer, Chief Medical Officer
- Mr. Badri DasuChief Engineering Officer$575,959
- Ms. Marina BozilenkoIndependent Director$62,283
- Ms. Jill BroadfootIndependent Director$56,349
- Dr. Stephen HoffmanIndependent Director$52,517
- Mr. Abhinav JainIndependent Director$57,074
- Mr. Mark WanIndependent Director$63,458
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 59
- Social
- 33
- Governance
- 65
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AcelRx Pharmaceuticals develops Niyad for acute kidney injury in hospital settings.
- Niyad targets dialysis circuits during CRRT for AKI patients in hospitals.
- LTX-608 is formulated for IV infusion to treat COVID and ARDS.
Weaknesses
- AcelRx employs only 19 full-time employees in San Mateo.
- The company has no products approved for commercial use yet.
- Niyad and LTX-608 are still in development stages.
Opportunities
- Niyad addresses the growing need for anticoagulants in dialysis centers.
- LTX-608 could expand to treat ARDS and DIC in hospitals.
- The firm's pre-filled syringes Fedsyra and PFS-02 may enter new markets.
Threats
- Niyad faces competition from existing anticoagulant therapies.
- LTX-608 development could be delayed by regulatory hurdles.
- The small team of 19 employees may struggle with scaling production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.